title: Evaluation of oxidative stress indices during treatment in pregnant women with intrauterine growth retardation.
abstract: BACKGROUND
  We investigated treatment-related changes in oxidative stress indices in intrauterine growth retardation (IUGR) during pregnancy. Four parameters of cell membrane destruction were measured: malondialdehyde, Schiff bases, lipid peroxides, and conjugated dienes.
  
  
  METHODS
  The study population included pregnant women under treatment in the Department of Obstetrics and Gynecology at the Medical University of Łódź in 1997-1999, divided into two groups: (I) - 30 healthy pregnant women, (II) - 31 pregnant women with a clinical and ultrasound diagnosis of IUGR. The course of treatment consisted of ten days of intravenous injections of cocarboxylase, Vitamin C, and solcoseryl as antioxidant factors. The parameters of oxidative stress were measured on the first day of hospitalization, after five days of treatment, and on the 10th day of treatment.
  
  
  RESULTS
  The mean value of MDA concentration in Group I was 2.03, vs. 2.39 in Group II. The mean value of conjugated dienes was 2.40 in Group I and 2.41 in Group II. The Schiff bases concentration in Group I was 8.03, as opposed to 8.83 in Group II. The concentration of lipid peroxides was 0.113 in Group I and 0.134 in Group II. We found that all the parameters of oxidative stress were higher in IUGR than in normal pregnancy. At the end of treatment a decrease was observed in all oxidative stress parameters.
  
  
  CONCLUSIONS
  IUGR is correlated with an increase in membrane damage parameters. Therapy for IUGR decreased the values of all indices of oxidative stress.
authors.affiliation: Department of Obstetrics and Gynecology, Medical University, Łódź, Poland.
authors.forename: Agata
authors.initials: A
authors.lastname: Karowicz-Bilińska
authors.forename: Jacek
authors.initials: J
authors.lastname: Suzin
authors.forename: Piotr
authors.initials: P
authors.lastname: Sieroszewski
mesh_terms: D000183:Actihaemyl / Q000627:therapeutic use; D000328:Adult; D001205:Ascorbic Acid / Q000627:therapeutic use; D005260:Female; D005317:Fetal Growth Retardation / Q000628:therapy*; D006801:Humans; D015227:Lipid Peroxidation; D018384:Oxidative Stress; D011247:Pregnancy; D013835:Thiamine Pyrophosphate / Q000627:therapeutic use
chemical_list: D000183:Actihaemyl; D001205:Ascorbic Acid; D013835:Thiamine Pyrophosphate